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ABSTRACT 
Objective: The aim of this study was to carry out a quality control test on a range of different production of cetirizine hydrochloride 10mg tablets 
and to compare the generic productions with the reference one in order to evaluate if there are any outstanding differences in terms of quality and 
price. 
Methods: Various pharmacopeias tests were carried out: weight variation test, disintegration test, dissolution test, as well as other tests such as: 
setting the diameter, thickness, tensile strength, friability and hardness test. The pharmaceutical equivalents were compared to the reference 
product in terms of similar dissolution factor (f2) of dissolution profiles and the evaluation of dissolution efficiency (DE). Tablet dissolution was 
carried out in a multi bath (n=6) dissolution test system (Varian Dissolution Apparatus 2) (50rpm, 37.0±0.5 ºC, bi distillated water 900 ml, pH 7.0). 
An UV-Vis spectrophotometer (Cary 100, Varian) was used to determine cetirizine concentration at wavelength 230.1 nm. Varian Hardness VK200, 
Guoming CS-2 friability apparatus and Guoming BJ-2 disintegration apparatus are used for the specific tests. 
Results: The study showed that all the products met with the standards of pharmacopoeia and that dissolution profiles were significantly the same 
but, however, there is also a remarkable difference in price.  
Conclusion: All the productions met the requirements and are within the limits of pharmacopoeia for the presented tests. Cetirizine reference 
product still sells well on the open pharmaceutical market even though it costs more and regardless of the fact that other generics have practically 
the same qualities.  
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INTRODUCTION 
According to Food and Drug Administration (FDA), when we say 
‘quality control’ we mean the total number of procedures carried out 
to ensure the identity and purity of a particular pharmaceutical 
product. Such procedures may range from the results of some simple 
chemical experiments to determine the identity, screening to 
uncover the presence of particular pharmaceutical substances and the 
more so the complicated requirements of pharmacopoeia 
monographs. A generic drug should be the same as a brand name drug 
in dosage, safety, strength, how it is taken, quality, performance, and 
intended use. The FDA (Food and Drug Administration), in order to 
issue approval for a generic drug product, has laid down quite a few 
strict, mandatory regulations on tests and procedures to guarantee 
that the generic drug can actually be a substitute for the brand name 
drug. The FDA bases its approval for substitution, on the "therapeutic 
equivalence," of generic drugs through specific scientific evaluations. 
By law, a generic drug product must contain identical amounts of the 
same active principal (s) as the brand name product. Drug products 
considered “therapeutically equivalent" have to have exactly the same 
effect as the brand name product [1]. 
In the framework of tablet quality control on the Albanian 
pharmaceutical market, the reference product (A) and two generic 
tablets (B,C) of cetirizine hydrochloride 10mg were subject to this study. 
Cetirizine is an antihistaminic-H1 and comes under class I in the 
range of active principles according to Biopharmaceutical 
Classification System (BCS) [2]. Cetirizine is also included in the 
fundamental drug list drawn up by the World Health Organization 
(WHO) which goes to explain the importance of this medicine on the 
pharmaceutical market.  
MATERIALS AND METHODS 
The materials used in this study included the reference product 
cetirizine hydrochloride tablet 10mg (A) and two generic ones (B, C) 
purchased on the pharmaceutical market in Tirana, Albania along 
with their respective prices (Table 1). 
Weight variation 
20 tablets from each product of cetirizine hydrochloride were 
weighed one by one through an analytical scale and the average 
weight was calculated together with the standard deviations and 
relative standard deviations (RSD). 
Hardness 
10 tablets of each brand were measured using Varian VK 200 for 
hardness. The mean value was calculated with standard deviation 
(SD). 
Diameter and thickness 
Caliber WT was used to measure the diameter and thickness of 10 
different tablets of each brand. The average diameter and thickness 
was evaluated along with the respective standard deviation (SD). 
Friability 
10 tablets were first weighed ()1 . The friability apparatus 
Guoming CS-2 was set at 25rpm for 4 min. The tablets were then 
accurately weighed (2). Formula (1) calculated the friability of the 
tablets.  
(1) friability = W1W2
W1
∗  100 
 
Disintegration 
6 tablets of different brands were subjected to a disintegration test 
with a Guoming BJ-2 disintegration apparatus set at 29-32 cycles per 
minute at a temperature of 37°C with 1L medium of distilled water.
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Table 1: It shows the materials used in the study 
Brand Pharmaceutical form Dose Expiry data  Price/tabler (€) 
Reference A Uncoated tablet 10mg Sept 2016 0.26 
Generic B Uncoated tablet 10mg Aug 2016 0.17 
Generic C Uncoated tablet 10mg May 2016 0.20 
  
Calibration curve 
100mg of cetirizine hydrochloride were dissolved in 50 ml of water, 
stirred with “ultrasonic” for 30 minutes and then filled with up to 100 
ml of water. The mother solution with a concentration of 1mg/ml, 
filtered beforehand, was then used to make up the standard solutions 
(5, 10, 20, 40 µg/ml). The diluted solutions were then scanned using a 
Varian Cary UV-Vis spectrophotometer in the range [200-400 nm]. 
Absorption maximum was obtained at 230.1 nm. A standard curve was 
plotted to study the linearity of Beer Lambert’s Law.  
Dissolution 
A dissolution test was carried out in line with a USP monograph, 
with a dissolution apparatus II Guoming RC-6, paddle type, 50 rpm 
at a temperature of 37°C with 900 ml water as medium. Aliquots of 
5 ml were taken at intervals of 5, 10, 20, 30, 45 minutes, and then 
replaced with the same medium (replacement method). The 
aliquots were properly diluted (1:100) and the respective 
absorbance was measured with the spectrophotometer at a 
maximum wavelength of 230.1 nm. The percentage of the drug 
released was calculated using the regression equation from the 
calibration curve by extrapolation.  
Comparing dissolution profiles 
The dissolution performance of each brand was developed according 
to USP guidelines. In order to characterize the drug release profile, 
parameters such as, t x% sampling time (a commonly used parameter 
of the Pharmacopoeias) and dissolution efficiency (DE) can be used. 
Data obtained from these parameters, to thoroughly understand the 
release mechanism, were fairly limited and said parameters should 
be associated among each other [3]. Dissolution performance was 
compared through:  
1. Extrapolating the t30 min, the percentage of drug released in a time 
frame of 30 minutes. 
2. Calculating similarity (f2) and difference (f1) factors [4] of the 
formula (3) and (4) first development by Moore and Flanner 1996. 
(2) f1 = ∑ |RtTt |nt
1∑ Rtnt
1  ∗  100 
3) f2 = 50 ∗ log{ [1 + 1
n
 Rt − Tt)2
n
t1
]0,5 ∗ 100 
Where: Rt dhe Tt were the percentages of drug release of the 
reference product and generic product in time t  
n was the number of points were the samples of both reference and 
generic were released above 80%. 
Values of f1 in the range of [0-15] and f2 in the range of [50-100] 
suggested that the dissolution profiles were somewhat the same. 
3. Calculating the dissolution efficiency from the formula (5). The 
dissolution efficiency of a pharmaceutical form (Khan and 
Rhodes 1972; Khan 1975) was defined as the area under the 
dissolution curve up to a certain time, t, expressed as a 
percentage of the area of the rectangle described by 100% 
dissolution in the same time [4]. 





Where: y is the percentage of drug dissolved in time t  
DE estimated the release of the active pharmaceutical principal 
into the absorptive medium. The determination of DE was to 
calculate the rhythm of release of the drugs in the simulated 
media so as to get a clear idea of the amount of drugs absorbable 
in the GIT. The dissolution efficiency was calculated for every six 
vessels and a mean value was obtained along with a confidence 
interval of 95%. A t test p-value was calculated in order to 
determine any significant difference in the %DE30 min of the 
generics compared to the reference product (significance 
difference *p<0,05). 
RESULTS AND DISCUSSION 
Weight variation 
All tablets complied with the standards of USP for weight variation 
[5], no more than two of the individual weights deviated from the 
average weight by more than 10%. The results are listed in table 1. 
Hardness 
The hardness test in a non-official pharmacopeia test indicated 
whether a tablet was too hard or too soft or friable. The 
recommended hardness value is 4-10 N [6], but even if the values 
are beyond this limit, the disintegration test should be carried out 
before rejecting the whole batch. All the tablets and requirements 
and are listed in table 1. 
Diameter and thickness  
The different tablets have the same diameter but differ in thickness. 
The results are listed in table 1. 
Disintegration 
All the tablets met with the standards set by USP on disintegration 
which is not more than 30 minutes [7]. All tablets disintegrated 
rapidly within 4 to 7 minutes. 
 
Table 2: Results of weight variation test, hardness test, diameter, thickness, friability and disintegration time. 












Reference A 0,1215 (1,10) 10,03±1.8 6.563±0,86 1,38±0,22 0,06% 4 
Generic B 0,1747 (0,77) 9,28±0.68 7,316±0,55 3,91±0,49 0,21% 7 
Generic C 0,1776 (1,85) 7,06±0.81 5,570±1,04 5,35±1,09 0,01% 5 
 
Dissolution  
The final results of the dissolution test on each tablet production are 
listed in table 2. The dissolution profiles can be seen in chart 2.  
All tablets dissolved within USP limits (more than 80% should be 
released in 30 minutes). It is obvious that the tablet dissolves very 
fast, within the first 5 minutes, on average more than 50% of the 
drug is released. 
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Table 3: Results of dissolution tests of different cetirizine hydrochloride tablets expressed in percentage drug release within certain time 
intervals 
%drug release (avg) 
Time (min) Reference A Generic B Generic C 
5 63% 57% 67% 
10 82% 84% 73% 
20 94% 93% 88% 
30 100% 103% 100% 
45 103% 107% 101% 
 
 
Fig. 1: Calibration curve of cetirizine hydrochloride in distilled water 
 
 
Fig. 2: Dissolution profile of cetirizine hydrochloride  tablets 10mg (Reference A, Generic B, Generic C) 
 
Table 4: Comparison and characterization of dissolution profiles by t30 min, dissolution efficiencies with 95% confidence intervals, and 
similarity/difference factors (f2 and f1) 
 t30 min %DE 30 min (CI) Similarity Factor f2 Difference Factor f1 
Reference A 100%  - - 
Generic B 103%  4 69 
Generic C 100%  5 61 
 
Comparison of dissolution profiles 
The dissolution profiles are characterized and compared through 
different parameters: first, t30 min sampling time (the % of drug 
release within 30 minutes from the beginning of the test), then the 
evaluation of %DE 30 min (dissolution efficiency at 30 minutes mean 
value of six vessels every 30 minutes with confidence intervals CI 
95%) as well as similarity and difference factors (f2 and f1). The 
results are shown in the table 3. 
As shown in table 3, the t 30 min values of the generics are similar to 
the reference (p=0, 16 for generic B and p=0, 46 for generic C) 
(*p<0,05), signaled for similarity in the dissolution process. 
Dissolution efficiency (%DE 30 min) values of the methods used in this 
study show no significant statistical difference between the 
reference product and the generic one (p=0, 22 for generic B and 
p=0, 19 for generic C) (*p<0,05). The factors of similarity and 
difference demonstrate similarity since the f1 values are within the 
range [0-15] and f2 values are within [50-100]. The 
factors f1 and f2 offer straightforward calculation and a simple 
measure of similarity between pairs of dissolution profiles. This is 
well suited to the qualitative determination of `similarity' as 
required by the FDA's SUPAC Guide. Because D. E. has a simple 
physical meaning, it is easier to interpret D. E. data than the 
corresponding f1 and f2 results [8]. The quality control test results 
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showed us that there is no obvious difference between the different 
generics and the reference product of cetirizine hydrochloride in 
terms of the parameters in weight variation test, disintegration test, 
dissolution test. Even other studies (Costa, 2001) shows that the 
quality control tests, especially the dissolution test, may serve as 
tools for comparing the generics with the reference product through 
similarity factor and dissolution efficiency [9]. 
CONCLUSION 
The different quality test results of cetirizine hydrochloride tablets 
10mg met with the requirements of pharmacopoeia. Weight 
variation tests showed that all tablets have a %RSD < 10%. Also the 
hardness test results were below the limit recommended. A 
difference between the tablets was seen in the diameter and 
thickness values which is most likely due to the different choices in 
production. Friability results were under the recommended limit of 
1%. Even the disintegration test results fell within the set limits of 
pharmacopoeia of not more than 30 minutes. The disintegration 
time was 4 min for the reference product Cetirizine and 7 min and 5 
min for generic B and C respectively. The rapid dissolution rate at the 
onset can be explained by the high solubility of the active 
pharmaceutical ingredient, Cetirizine (Class I according to BSC). It was 
demonstrated that the t30 min of the products conformed to 
pharmacopoeia standards (t30 min>80%). The comparison between 
products was carried out through the comparison of different 
parameters of the dissolution profile. All proved that there are no 
significant differences between the products. The factors f1 and f2 offer 
an easy calculation and a simple measure of similarity between pairs 
of dissolution profiles. This is well suited to the qualitative 
determination of `similarity' as required by the FDA's SUPAC (Scale-
Up and Post Approval Changes) Guide. Because D. E. has a simple 
physical meaning, it is easier to interpret D. E. data than the 
corresponding f1 and f2 results [9].  
The basic difference lies in the price of the products sold on the 
Albanian pharmaceutical market. The brand Cetirizine tablet has a 
higher price compared to the other generics. The percentage gap, in 
terms of price between the reference product and the generic B and 
C, varies from 34% to 23%. So to sum up, the Cetirizine reference 
product is still competitive on the open pharmacy. eutical market 
even though it costs more than the other generics which have 
practically the same quality. 
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